ClinicalTrials.gg
Not yet recruitingNCT07617870PROMISEUpdated Jun 1, 2026

Pro-urokinase for Extended-Window Posterior Circulation Stroke

A Phase 3 interventional study of rhPro-UK and placebo in Acute Ischemic Stroke, sponsored by The First Affiliated Hospital of Zhengzhou University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by The First Affiliated Hospital of Zhengzhou University · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
160th of 563
586 · median 266
Started
2026
with 121 others
Phase 3
109 of 750
63 open now
Primary completion
2027-12
later than 255 of 395 live
Registered
701st of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 160th largest by planned enrollment of the 563 interventional ones that give a count, is one of 122 that started in 2026, is one of 109 in phase 3, reaches primary completion later than 255 of the 395 other live ones, and was the 701st registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.

Read the detailed description

Stroke is the second leading cause of death and the third leading cause of disability worldwide. Posterior circulation ischemic stroke (PCIS) accounts for approximately 20% of all ischemic strokes. Due to involvement of critical structures such as the brainstem and cerebellum, PCIS is associated with rapid neurological deterioration, high disability and mortality rates, and often presents with atypical clinical manifestations, leading to frequent misdiagnosis and delayed treatment. Consequently, many patients miss the conventional 4.5-hour intravenous thrombolysis window. However, the posterior circulation possesses relatively abundant collateral circulation and stronger ischemic tolerance, resulting in a lower risk of intracranial hemorrhage after thrombolysis and suggesting the potential feasibility of an extended therapeutic window.

In recent years, multiple studies have promoted a paradigm shift in acute ischemic stroke management from a "time window"-based strategy to a "tissue window"-based strategy. Trials including EXTEND, TRACE-III, HOPE, and OPTION demonstrated that intravenous thrombolysis administered within 4.5-24 hours after symptom onset, guided by perfusion imaging selection, could still improve functional outcomes. The EXPECTS study further showed that patients with posterior circulation stroke who were not candidates for endovascular thrombectomy could benefit from alteplase treatment within 4.5-24 hours, with a relatively low risk of symptomatic intracranial hemorrhage. Nevertheless, limitations such as a high proportion of mild stroke cases, non-randomized study design, and baseline imbalance indicate that stronger evidence is still required.

Recombinant human prourokinase (rhPro-UK), a novel fibrin-specific thrombolytic agent independently developed in China, has advantages over rt-PA, including lower systemic fibrinolytic activation and reduced bleeding risk, making it potentially more suitable for extended-window thrombolysis. The PROST-2 trial demonstrated that rhPro-UK was non-inferior to rt-PA in efficacy among patients treated within 4.5 hours after acute ischemic stroke onset, while significantly reducing symptomatic intracranial hemorrhage and systemic bleeding events, highlighting its favorable safety profile and potential for extended-window application.

Therefore, this study aims to evaluate whether intravenous thrombolysis with rhPro-UK, compared with standard medical therapy, can achieve better 90-day functional outcomes and improved safety in patients with imaging-confirmed posterior circulation acute ischemic stroke presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Recombinant human prourokinase (rhPro-UK)
  • Posterior circulation ischemic stroke
  • Extended-window thrombolysis
  • Intravenous thrombolytic therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years;
  2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);
  3. Imaging criteria:

    1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
    2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
  4. NIHSS score 4-25;
  5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);
  6. Signed from the patient or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Planned endovascular treatment;
  2. Contradictory to MRI examination;
  3. MRI image not qualified for evaluation;
  4. Serious neurological deficits before onset (mRS≥2);
  5. Obvious head injuries or strokes within 3 months;
  6. Subarachnoid or intracranial hemorrhage;
  7. History of intracranial hemorrhage;
  8. Intracranial tumor, arteriovenous malformation or aneurysm;
  9. Intracranial or spinal cord surgery within 3 months;
  10. Active internal hemorrhage;
  11. count of \<100000/mm3;
  12. Aortic arch dissection;
  13. Heparin therapy within 24 hours;
  14. Oral warfarin is being taken and >1.6 or APTT abnormal;
  15. Oral anticoagulation therapy;
  16. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
  17. Blood glucose \< 50 mg/dl (2.7mmol/L);
  18. Pregnancy;
  19. Neurological deficit after epileptic seizures;
  20. Major surgery within 1 month;
  21. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  22. Myocardial infarction within 3 months;
  23. Allergy to study drugs;
  24. Unlikely to adhere to the trial protocol or follow-up;
  25. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  26. Participation in other interventional clinical trials within the previous 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
586 participants (estimated)

Study arms

  • Experimental
    rhPro-UK group

    On Day 1 after randomization, patients will receive intravenous rhPro-UK plus aspirin placebo (300 mg). From day 2 to day 90, patients will receive standard care according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2023).

    Drug: rhPro-UK · Drug: placebo

  • Active comparator
    Control group

    On Day 1 after randomization, patients will receive rhPro-UK placebo plus oral aspirin (300 mg). From day 2 to day 90, patients will receive standard care according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2023).

    Drug: Aspirin · Drug: Placebo

Interventions

  • DrugrhPro-UK

    rhPro-UK (5 mg/vial), to maximum of 35mg

  • Drugplacebo

    Asprin (placebo)

  • Asprin (300mg)

  • DrugPlacebo

    rhPro-UK(placebo)

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS)

    Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days.

    Time frame: 90 ± 7 days]

Secondary outcomes

  1. Modified Rankin Scale (mRS)

    Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.

    Time frame: 90 ± 7 days

  2. Modified Rankin Scale (mRS)

    Ordinal shift analysis of mRS at 90 days

    Time frame: 90 ± 7 days

  3. National Institutes of Health Stroke Scale (NIHSS)

    NIHSS change from baseline at 24 hours and 7 days.

    Time frame: 24 hours and 7 days

  4. Barthel (BI)

    Barthel Index score at 90 ± 7 days.

    Time frame: 90 ± 7 days

  5. EuroQol 5-Dimension (EQ-5D)

    Quality of life measured by EQ-5D scale at 90 ± 7 days.

    Time frame: 90 ± 7 days

  6. Modified Rankin Scale (mRS)

    1. Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days. 2. Ordinal distribution of mRS at 90 ± 7 days

    Time frame: 90 ± 7 days

Other outcomes

  1. Symptomatic intracranial hemorrhage (sICH)

    Proportion of subjects with symptomatic intracranial hemorrhage (sICH) at 36 hours (according to the ECASS III criteria).

    Time frame: 36 hours

  2. Death

    Overall mortality rate at 90 days.

    Time frame: 90 days

  3. Systemic bleeding

    Systemic bleeding at 90 days (according to the GUSTO criteria)

    Time frame: 90 days

  4. Adverse events (AEs)/ serious adverse events (SAEs)

    Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 days.

    Time frame: 90 days

07

Study locations

1 site
  • Department of Neurology, the First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

Of 143 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 18 months is below that.

Counting every sponsor, half of 165 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 1, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07617870
Responsible party
Bo Song (chief physician、Professor, The First Affiliated Hospital of Zhengzhou University) — Principal investigator
First posted
Jun 1, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

Bo Song, MD
Contact
fccsongb@zzu.edu.cn
+86-371-66278068

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion